Peptides for Menopause Research: NAD+, GHK-Cu, MOTS-c, and Aging Pathways

The biological changes of menopause, including NAD+ decline, collagen loss, metabolic slowdown, and mitochondrial dysfunction, have mechanistic overlap with research on NAD+, GHK-Cu, MOTS-c, and SS-31. This article maps those intersections. None of these compounds alter estrogen or other sex hormone levels; they are not studied as menopause treatments. Their research interest comes from addressing downstream consequences of hormonal transition.

Menopause: Permanent cessation of ovarian function and menstruation (12 consecutive months without menstrual cycles), involving progressive decline of estradiol, progesterone, and inhibin.

Estrogen: Steroid hormones (primarily estradiol in reproductive years) with pleiotropic effects including cardiovascular protection, bone maintenance, skin collagen support, mitochondrial function support, and anti-inflammatory signaling.

NAD+ (nicotinamide adenine dinucleotide): Mitochondrial electron carrier and sirtuin substrate. Estrogen receptor signaling upregulates NAMPT, the rate-limiting NAD+ salvage biosynthesis enzyme.

NAMPT (nicotinamide phosphoribosyltransferase): Rate-limiting enzyme in NAD+ salvage pathway. Estrogen receptor signaling drives NAMPT expression; declining estrogen reduces NAMPT activity.

Collagen synthesis: Fibroblast-driven production of structural proteins. Estrogen upregulates collagen synthesis; post-menopausal collagen decline is well-documented.

Lysyl oxidase (LOX): Enzyme that cross-links collagen and elastin, strengthening extracellular matrix. Estrogen upregulates LOX; post-menopause decline contributes to skin laxity.

Menopause represents the withdrawal of estrogen's multiple protective mechanisms: cardiovascular protection, bone density support, skin matrix maintenance, mitochondrial function support, and anti-inflammatory signaling. The resulting biology resembles, in some respects, accelerated systemic aging.

Researchers studying aging biology have noted that the menopausal transition provides a natural experiment in which hormonal withdrawal effects on multiple organ systems can be studied over a compressed timeframe.

This makes menopause an interesting context for compounds that address aging biology broadly. NAD+, MOTS-c, GHK-Cu, and SS-31 each target mechanisms relevant to aging that are also specifically affected by estrogen withdrawal.

NAMPT (the rate-limiting NAD+ biosynthesis enzyme) has estrogen response elements in its promoter: estrogen receptor signaling directly drives NAMPT expression. When estrogen falls, NAMPT expression decreases, reducing NAD+ biosynthesis capacity.

This means the well-documented age-related NAD+ decline may be accelerated by the menopausal transition in women, creating compounded NAD+ depletion (aging-related decline plus menopause-related NAMPT reduction).

Published data from human aging studies shows correlation between lower NAD+ precursor metabolites and poorer metabolic outcomes in older women. The mechanistic pathway (estrogen receptor-mediated NAMPT regulation) provides a plausible causal link, though direct menopause-specific NAD+ data is limited.

See NAD+ guide, NAD+ longevity trial review, mitochondria and aging research.

The perimenopausal transition is associated with increased central adiposity, reduced insulin sensitivity, lower resting metabolic rate, and impaired exercise recovery. These changes are specifically accelerated by estrogen withdrawal, documented in published longitudinal transition studies.

MOTS-c's AMPK/GLUT4 mechanism addresses the insulin sensitivity and skeletal muscle metabolic components of this shift. AMPK activation improves glucose uptake independent of insulin. AMPK also drives PGC-1alpha-mediated mitochondrial biogenesis, potentially offsetting reduced mitochondrial density from aging and estrogen withdrawal.

Published MOTS-c research in aged rodents shows metabolic restoration toward younger-animal levels. Whether this aging-related data is specifically applicable to menopausal transition (versus general aging) is an open research question.

See MOTS-c diabetes insulin research and MOTS-c guide.

The menopausal transition accelerates skin aging. Published research documents women lose approximately 30% of dermal collagen in the first 5 post-menopausal years. This rapid early decline is driven by withdrawal of estrogen's collagen-stimulating effects: estrogen upregulates fibroblast collagen production and lysyl oxidase (LOX) which cross-links collagen fibrils.

GHK-Cu gene expression research shows it activates 4,000+ genes including collagen genes (COL1A1, COL1A2), lysyl oxidase (LOXL2), and other extracellular matrix genes that substantially overlap with what estrogen normally upregulates.

Published topical GHK-Cu skin aging research demonstrates improved skin thickness, collagen density, and laxity markers. The evidence includes studies in post-menopausal women with moderate evidence quality.

See GHK-Cu guide, GHK-Cu gene expression research, GHK-Cu protocol guide.

Published research documents mitochondrial dysfunction as an early biological change during perimenopausal transition, preceding clinical menopause. Estrogen supports mitochondrial function through multiple mechanisms: upregulating Complex I expression, promoting mitochondrial biogenesis via PGC-1alpha, and supporting antioxidant enzyme systems.

As estrogen declines, published research in perimenopausal women and animal models of ovarian failure shows: reduced mitochondrial membrane potential, increased ROS, lower ATP output per cell, and increased morphological abnormalities in multiple tissue types.

SS-31's cardiolipin stabilization mechanism directly addresses this biology. Cardiolipin oxidation is a key event in mitochondrial dysfunction; SS-31's prevention of this oxidation preserves ETC complex organization. Published SS-31 data in cardiac and skeletal muscle aging models shows mitochondrial function restoration.

See SS-31 guide, SS-31 heart failure research, SS-31 cardiolipin deep dive.

Understanding evidence quality in menopause-relevant biology:

GHK-Cu: Published topical skin aging studies, including some in post-menopausal women. Moderate clinical evidence for skin biology. No published systemic menopause research.

NAD+: Strong mechanistic evidence for NAMPT-mediated connection to estrogen status. Human aging trial data exists but is not menopause-specific. Mechanistic link is well-founded; direct menopause-outcome data is limited.

MOTS-c: Published aging and metabolic research is relevant to menopausal metabolic changes, but MOTS-c research was not conducted in specifically menopausal populations. Mechanistic extrapolation from aging data.

SS-31: Published mitochondrial function and aging research is mechanistically relevant; no published SS-31 research in perimenopausal or menopausal women specifically.

The common thread: well-characterized mechanisms intersecting with menopause transition biology, but clinical research in menopausal populations is limited or absent for most. This represents a significant research gap with clear mechanistic rationale.

This article is not a discussion of menopause treatment. None of these compounds alter sex hormone levels, replace estrogen, or address the primary hormonal deficit of menopause. Research interest is in downstream biological consequences of hormonal transition.

Researchers studying peptide biology in post-menopausal populations should carefully define research endpoints (skin biology, metabolic function, mitochondrial markers, NAD+ levels) and ensure therapeutic claims are not made beyond what evidence supports.

The hormonal and metabolic complexity of the perimenopausal transition means study designs need careful accounting for menopausal stage, time since menopause, hormonal therapy history, and other confounders.

NAD+: NAD+ guide, NAD+ longevity trial review. GHK-Cu: GHK-Cu guide, GHK-Cu protocol guide, GHK-Cu gene expression research. MOTS-c: MOTS-c guide, MOTS-c deep dive, MOTS-c diabetes insulin research. SS-31: SS-31 guide, SS-31 cardiolipin deep dive. Context: mitochondria and aging research.